How do GLP-1 medications work?

GLP-1 receptor agonists (semaglutide, tirzepatide) mimic gut hormones that signal satiety, slow gastric emptying, and modulate insulin response. Patients typically experience reduced appetite and food noise. Published trials show 15-20%+ body weight loss with sustained use.

Are GLP-1 medications safe?

Generally well-tolerated. Common side effects: nausea, constipation, diarrhea. Less common but more serious: pancreatitis, gallbladder issues, gastroparesis. Contraindicated in personal/family history of medullary thyroid carcinoma or MEN-2. Must be prescribed and monitored by a qualified physician.

What's compounded semaglutide?

Compounding pharmacies have been allowed to produce semaglutide during FDA shortage status, but quality varies and FDA scrutiny is increasing. Brand-name medications (Wegovy, Ozempic, Zepbound, Mounjaro) have established quality control. Discuss source with your provider.

What happens if I stop?

Most patients regain substantial weight after discontinuation. Current data suggests GLP-1s are typically a long-term medication, similar to medications for hypertension or diabetes. Discuss long-term plan with your provider before starting.

Do I need body contouring after weight loss?

Significant weight loss often produces excess skin that doesn't retract. Non-surgical skin tightening produces modest results in mild cases; surgical excision (panniculectomy, brachioplasty, mastopexy, etc.) is required for advanced cases. Consult a board-certified plastic surgeon experienced with post-weight-loss patients.

What does 'medically supervised' actually mean?

True medical supervision includes initial workup (labs, medical history), regular monitoring (typically monthly), dose adjustments based on response, and follow-up for side effects. Many telehealth programs offer minimal supervision, ask specifically about provider availability and monitoring.

How do I evaluate a weight-management provider?

Look for physicians certified in obesity medicine (ABOM), endocrinologists, or internists with metabolic-health focus. Ask about supervision frequency, lab requirements, and long-term care plan. Be cautious of programs prioritizing rapid sign-up over thorough evaluation.

The leadStraight reporting on GLP-1s, weight-loss medicine, and the programs behind them.

Two unbranded medicine cartons and a syringe on a bright white pharmacy counter

The Medications

Photo illustration

Wegovy generic name: semaglutide, and why a real generic Wegovy exists in Canada but not in the US

The Wegovy generic name is semaglutide, the same molecule sold as Ozempic and Rybelsus. In 2026 a true generic Wegovy was approved in Canada, and the FDA tentatively approved a generic Ozempic, yet neither can be sold in a US pharmacy. The word "generic" now means three different things depending on who is saying it.

Reviewed Sep 20265 sources cited

By Maeve Castellucci · September 30, 2026 · 6 min read

Across the desk

Explainer

What Actually Happens When You Stop a GLP-1 Medication

The biology of discontinuation is predictable, not mysterious. Here is what the data show about appetite rebound, weight regain, and how supervised programs plan for the off-ramp.

August 3, 2026 · Jonas Whitlock

Myth Check

Myth Check: Do GLP-1 Medications Melt Your Muscle Along With Your Fat?

Roughly a quarter to a third of weight lost on medications like semaglutide and tirzepatide is lean mass. Here is what that number actually means, why it is not automatically alarming, and what supervised programs do about it.

August 1, 2026 · Kavya Brandstrom

Explainer

The GLP-1 Plateau: Why Medically Supervised Weight Loss Stalls, and What Clinicians Actually Do Next

Almost everyone on semaglutide or tirzepatide eventually stops losing weight. The plateau is not a failure of willpower or the drug. It is predictable physiology, and supervised programs plan for it.

July 30, 2026 · Jonas Whitlock

The full file

Everything we have reported

64 stories

Pulling the next stories

Common questions

What readers
ask us.

GLP-1 receptor agonists (semaglutide, tirzepatide) mimic gut hormones that signal satiety, slow gastric emptying, and modulate insulin response. Patients typically experience reduced appetite and food noise. Published trials show 15-20%+ body weight loss with sustained use.

The Briefing